Niraparib metabolite M1
≥99%
- Product Code: 101676
CAS:
1476777-06-6
| Molecular Weight: | 321.37 g./mol | Molecular Formula: | C₁₉H₁₉N₃O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Niraparib metabolite M1 is primarily studied in the context of cancer treatment, particularly in relation to its parent compound, niraparib, which is a PARP inhibitor. Its applications are largely centered around understanding the pharmacokinetics and pharmacodynamics of niraparib, as it plays a role in how the drug is metabolized and excreted in the body. Researchers analyze this metabolite to assess its contribution to the overall efficacy and safety profile of niraparib in patients, especially those with ovarian cancer, breast cancer, and other malignancies where PARP inhibition is beneficial. Additionally, studying this metabolite helps in identifying potential drug-drug interactions and optimizing dosing regimens to minimize adverse effects while maintaining therapeutic effectiveness.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | €406.02 |
+
-
|
| 0.005 | 10-20 days | €1,488.74 |
+
-
|
Niraparib metabolite M1
Niraparib metabolite M1 is primarily studied in the context of cancer treatment, particularly in relation to its parent compound, niraparib, which is a PARP inhibitor. Its applications are largely centered around understanding the pharmacokinetics and pharmacodynamics of niraparib, as it plays a role in how the drug is metabolized and excreted in the body. Researchers analyze this metabolite to assess its contribution to the overall efficacy and safety profile of niraparib in patients, especially those with ovarian cancer, breast cancer, and other malignancies where PARP inhibition is beneficial. Additionally, studying this metabolite helps in identifying potential drug-drug interactions and optimizing dosing regimens to minimize adverse effects while maintaining therapeutic effectiveness.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :